Skip to main content
. 2020 May 21;9(5):446. doi: 10.3390/antiox9050446

Figure 5.

Figure 5

The expression of phase detoxifying enzymes. (A,B) The effect of myricetin (15 mg/kg) and B[a]P (2 mg/kg) treatment on CYP1A1 and CYP1B1 enzyme expression in the liver of Sprague-Dawley rats. (C) The effect of myricetin (10 μM) and B[a]P (10 μM) treatment on CYP1A1, GST, and ABCC2 enzyme expression in HepG2 cells. (D) Quantitative evaluation of relative protein expression of CYP1A1, GST, and ABCC2. All treatment groups are significantly different when compared with controls (** p < 0.01, *** p < 0.001) and B[a]P (### p < 0.001). Tukey’s multiple comparison test. M: myricetin.